Diabetic Nephropathy

Updated ADA Guideline Recommends Combo Tx for Type 2 Diabetes With CKD

Publish Date September 2, 2020

The 2020 ADA guideline update reflects evidence from recent major trials with cardiovascular and renal outcomes.

Dapagliflozin Reduces Kidney Failure Risk, Prolongs Survival in CKD

Publish Date September 1, 2020

Dapagliflozin appears to preserve kidney function and improve survival in patients with chronic kidney disease whether or not they have type 2 diabetes.

Empagliflozin Beneficial in Heart Failure With Reduced Ejection Fraction

Publish Date August 31, 2020

In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.

Boxed Warning Removed From Canagliflozin Labeling

Publish Date August 28, 2020

The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”

Trial Investigating Dapagliflozin in CKD Meets All End Points

Publish Date August 3, 2020

The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.

Long-Term Risk for Severe Kidney Disease High in Those With T2DM

Publish Date July 24, 2020

Onset at younger age with longer diabetes duration may add to risk for end-stage kidney disease.

High Prevalence of Americans Have Conditions Linked to Severe COVID-19

Publish Date July 27, 2020

Median prevalence of any underlying medical condition is 47.2% for residents in all 50 states, DC.

Increased Renal ACE2 in Diabetic Nephropathy May Up COVID-19 Kidney Infection Risk

Publish Date July 22, 2020

SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 on cell surfaces. Investigators performed a comparative analysis of specimens of diabetic kidney disease tissue and healthy tissue for ACE2 expression.

Finerenone Found to Delay Progression of Diabetic Kidney Disease

Publish Date July 17, 2020

Early results from the phase 3 FIDELIO-DKD study also show that finerenone reduces the risk for a cardiovascular secondary endpoint in patients with diabetic kidney disease.

Allopurinol Found Not to Prevent Kidney Disease Progression in Key Populations

Publish Date June 25, 2020

In separate randomized controlled trials, allopurinol had no significant effect on kidney function decline.